Negative but not futile: MAGE-A3 immunotherapeutic for melanoma
Mené dans 31 pays sur 1 391 patients atteints d'un mélanome de stade IIIB ou IIIC ayant subi une résection complète, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité d'une immunothérapie dispensée par injection intramusculaire avec un antigène MAGE-A3 en traitement adjuvant
Vaccines are one of the most effective tools that modern medicine can use against many common infectious diseases. Although cancer-associated antigens often trigger an immune response, the development of effective vaccines for cancer has been a lengthy and complicated process. Effective antigen presentation to the immune system requires an antigen fragment to be bound to the groove of the MHC class I protein on the antigen-presenting cell and be effectively presented to a matching T-cell receptor on a naive CD8 T cell along with a costimulatory signal
The Lancet Oncology , commentaire, 2017